Physician profile
Cephas Mujuruki
NPI 1376778951
$6,101.69
in general payments reported to CMS, 2019-2025
25 companies · $2,139 in 2025
The $2,139 reported for 2025 was more than what 87% of Sleep Medicine (Family Medicine) providers received nationally (typical 2025 total: $557).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $141 · 2021: $107 · 2022: $313 · 2023: $1,071 · 2024: $1,805 · 2025: $2,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,035 · Travel and Lodging: $1,410 · Education: $369 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,035.04 |
| Travel and Lodging | $1,409.96 |
| Education | $368.93 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $2,865.35 | 2023-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $798.50 | 2021-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $662.54 | 2023-2025 | Lumryz |
| Novo Nordisk INC | $434.18 | 2019-2024 | Rybelsus, Ozempic, Saxenda |
| Itamar Medical INC | $201.77 | 2022-2024 | Watchpatone |
| Harmony Biosciences LLC | $178.91 | 2022-2025 | Wakix |
| Astrazeneca Pharmaceuticals Lp | $134.64 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $126.63 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.15 | 2022-2024 | |
| Glaxosmithkline, LLC. | $106.29 | 2019-2023 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $84.50 | 2019-2020 | |
| Philips North America LLC | $68.43 | 2023-2025 | Home Pi Undivided |
| Amarin Pharma, INC. | $49.94 | 2019-2020 | |
| Lilly USA, LLC | $49.53 | 2020-2025 | Zepbound |
| Janssen Pharmaceuticals, INC | $31.94 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $27.36 | 2019-2021 | |
| Dexcom, INC. | $26.25 | 2024 | Dexcom G6 Transmitter |
| Nalpropion Pharmaceuticals LLC | $25.32 | 2019 | |
| Sumitomo Pharma America, INC. | $25.08 | 2025 | Gemtesa |
| Fisher & Paykel Healthcare INC | $19.68 | 2023 | Fisher & Paykel Healthcare |
| Allergan, INC. | $19.46 | 2020 | |
| Astellas Pharma US INC | $16.86 | 2019 | |
| Abbott Laboratories | $16.14 | 2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $11.26 | 2020 | |
| Zyla Life Sciences, INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cephas Mujuruki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.